Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3

Biomarkers

Volumn 4, Issue 2, 1999, Pages 129-134

  Yilmaz, Necat ^a   Aynacioglu, A Sükrü ^a   Erbagci, Binnur ^a   Cascorbi, Ingolf ^b   Roots, Ivar ^b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Molecular epidemiology; N acetyltransferase; Polymorphism; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; ARYLAMINE ACETYLTRANSFERASE; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; DNA POLYMORPHISM; DRUG ACETYLATION; FEMALE; HUMAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; TURKEY (REPUBLIC);

EID: 0032976721     PISSN: 1354750X     EISSN: None     Source Type: Journal    
DOI: 10.1080/135475099230930     Document Type: Article

References (24)

1. AGUNDEZ, J. A. G., OLIVERA, M., LADERO, J. M., LESCUR, A. R., LEDESMA, M. C., RUBIO, M. D., MEYER, U. A. and BENITEZ, J. 1996, Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics, 6, 501-512.
2. AMBROSONE, C. B., FREUDENHEIM, J. L., GRAHAM, S., MARSHALL, J. R., VENA J. E., BRASURE, J. R., MICHALEK, A. M., LAUGHLIN, R., NEMOTO, T., GILLENWATER, K. A. and SHIELDS, P. G. 1996, Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. Journal of the American Medical Association, 276, 1474-1501.
3. AYNACIOGLU, A. S., CASCORBI, I., MROZIKIEWICZ, P. M. and ROOTS, I. 1997, Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics, 7, 327-331.
4. BEGENT, R. 1984, The value of carcinoembryogenic antigen measurement in clinical practice. Annals of Clinical Biochemistry, 21, 231-238.
5. BROCKMÖLLER, J., CASCORBI, I., KERB, R. and ROOTS, I. 1996, Combined analysis of inherited polymorphisms in arylamine N-acetyltransferasse 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Research, 56, 3915-3925.
6. CAPORASO, N. and GOLDSTEIN, A. 1995, Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics, 5, 59-63.
7. CAPORASO, N., LANDI, M. T.and VINEIS, P. 1991, Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1, 4-19.
8. CASCORBI, I., DRAKOULIS, N., BROCKMÖLLER, J., MAURER, A., SPERLING, K. and ROOTS, I. 1995, Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. American Journal of Human Genetics, 57, 581-592.
9. CASCORBI, I., BROCKMÖLLER, J., MROZIKIEWICZ, P. M., BAUER, S., LODDENKEMPER, R. and ROOTS, I. 1996, Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Research, 56, 3961-3966.
10. COOPER, E. H., DE MELLO JR, J. P. and GILES, G. R. 1989, Biochemical markers in gastrointestinal malignancies. Arquivos de Gastroenterologia. 26, 131-140.
11. EVANS, D. A. P. 1992, N-acetyltransferase. In Pharmacogenetics of Drug Metabolism, W. Kalow, ed. (New-York: Pergamon), pp. 95-178.
12. GIL, J. P. and LECHNER, M. C. 1998, Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis, 19, 37-41.
13. GONZALEZ, F. J. and IDLE, J. R. 1994, Pharmacogenetic phenotyping and genotyping: present status and future potential. Clinical Pharmacokinetics, 26, 59-70.
14. GRANT, D. M., TANG, B. K. and KALOW, W. 1984, A simple test for acetylator phenotype using caffeine. British Journal of Clinical Pharmacology, 17, 459-464.
15. HEIN, D. W. 1988, Acetylator genotype and arylamine-induced carcinogenesis. Biochimica et Biophysica Acta, 948, 37-66.
16. HEIN, D. W., DOLL, M. A., RUSTAN, T. D., GRAY, K., FENG, Y., FERGUSON, R. J. and GRANT, D. M. 1993, Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis, 14, 1633-1638.
17. HERBETH, B. and BAGREL, A. 1980, A study of factors influencing plasma CEA levels in an unselected population. Oncodevelopmental Biology and Medicine, 1, 191-198.
18. KINZLER, K. and VOGELSTEIN, B. 1995, Colorectal tumors. In The Metabolic and Molecular Basis of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle, eds (USA: Mc Graw-Hill), pp. 643-663.
19. LANG, N. P., CHU, D. Z. J., HUNTER, C. F., KENDALL, D. C., FLAMMANG, T. J. and KADLUBAR, F. F. 1986, Role of aromatic amine acetyltransferase in human colorectal cancer. Archives of Surgery, 121, 1259-1261.
20. LUTZ, W., KRAJEWSKA, B. and PILACIK, B. 1997, Determination of tissue polypeptide antigens (TPA) and carcinoembryonic antigen (CEA) in serum: its value in the preliminary cancer risk assessment in asbestos exposed workers. International Journal of Occupational Medicine and Environmental Health, 10, 259-265.
21. MASHIMOTO, M., SUZUKI, T., ABE, M. and DEGUSHI, T. 1992, Molecular genotyping of N-acetylation polymorphism to predict phenotype. Human Genetics, 90, 139-143.
22. MROZIKIEWICZ, P. M., CASCORBI, I., BROCKMÖLLER, J. and ROOTS, I. 1996, Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clinical Pharmacology and Therapeutics, 59, 376-382.
23. VATSIS, K. P., WEBER, W. W., BELL, D. A., DUPRET, J. M., EVANS, D. A. P., GRANT, D. M., HEIN, D. W., LIN, H. J., MEYER, U. A., RELLING, M. V., SIM, E., SUZUKI, T. and YAMAZOE, Y. 1995, Nomenclature for N-acetyltransferases. Pharmacogenetics, 5, 1-17.
24. Wu, T. J. 1996, Diagnosis and management of cancer using serologic tumor markers. In Clinical Diagnosis and Management by Laboratory Methods, John Bernard Henry, ed. (Philadelphia: WB Saunders Co), pp. 1064-1080.